Zydus Lifesciences (BOM:532321) Total Current Assets : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Zydus Lifesciences's total current assets for the quarter that ended in Dec. 2024 was ₹0 Mil.

Zydus Lifesciences Total Current Assets Historical Data

The historical data trend for Zydus Lifesciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Total Current Assets Chart

Zydus Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Current Assets

Get a 7-Day Free Trial

87,154.00

87,160.00

122,614.00

100,164.00

115,014.00

Zydus Lifesciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															-	115,014.00	-	121,569.00	-

Zydus Lifesciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Zydus Lifesciences's Total Current Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	13797	+	54860	+	34419	+	11938
	=	115,014

Zydus Lifesciences's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0	+	0	+	0	+	0
	=	0

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Zydus Lifesciences (BOM:532321) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Zydus Lifesciences's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	0	+	0.75 * 0	+	0.5 * 0
=	0

Zydus Lifesciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Total Current Assets

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines